The Federal Commission for the Protection against Health Risks (Cofepris) reported on the approval of the health registration of sacituzumab govitecanan innovative biotechnological medicine for the treatment of triple-negative breast cancer in advanced stages or with metastasis.
According to the Biweekly Therapeutic Expansion Report, sacituzumab govitecan is one of the 14 approved drugs.
READ: UNAM sends humanitarian aid to those affected by Hurricane “John”
In addition, among the newly registered health supplies there are 11 clinical trials and 96 medical devices.of which 42 were designed specifically for healthcare.
These include ventricular assist systems, percutaneous balloon catheters for coronary angioplasty, aortic valve dilation balloon catheters, intrauterine devices, and implantable neurostimulators, among others.
Cofepris also authorized 34 medical teams with manual resuscitators, contrast injection systems, negative pressure wound therapy devices, bone drills, manual lung resuscitators and kidney transporters.
What is Sacituzumab govitecan?
According to the National Cancer Institute, sacituzumab govitecan, also called Trodelvy, It is a type of antibody-drug conjugate. It is defined as a medicine used to treat various types of breast cancer or urothelial cancer (type of bladder cancer) in adults who have previously been treated with therapy.
YOU CAN READ: Mayan Train Stations that suspend service due to Hurricane Milton
It contains the monoclonal antibody sacituzumab that binds to the TROP2 protein present on some cancer cells, however, it also contains an anti-cancer drug called SN-38 that can probably help destroy these cells.
Sacituzumab govitecan is already in studies to be used in the treatment of other types of cancer.
YC
